Currently, NQO1-mediated chemotherapy resistance has been confirmed in cholangiocarcinoma tumor cells [31], and the targeted metabolism drug KP372-1 mediated by NQO1 has effectively inhibited tumor growth in xenograft models [32]. Here, NQO1 is linked to neoplasm.